CellPoint: Galapagos : to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies - Form 6-K

(marketscreener.com) Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies Potential for paradigm shift in CAR-T therapy with CellPoint's decentralized point-of-care manufacturing model, in partnershipwith Lonza,and AboundBio'scutting-edge fully humanantibody-based capabilities,...https://www.marketscreener.com/quote/stock/GALAPAGOS-NV-6464/news/Galapagos-to-acquire-CellPoint-and-AboundBio-to-accelerate-access-to-next-generation-cell-therapie-40799457/?utm_medium=RSS&utm_content=20220623